CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Roche scraps two Ionis-partnered Huntington’s drugs

rejectedNegative
AI Analysis

Summary

Roche has discontinued two Huntington's disease drugs developed in partnership with Ionis. The decision represents a setback in the companies' collaboration to develop treatments for this neurodegenerative disorder.

Outcome Details

Program discontinuation

Importance:6/10
Sentiment:
-0.80
program_discontinuationhuntingtons_diseasepartnershipdrug_development
Related Companies

Read the original article

Published by yahoo_finance on July 9, 2026 4:53 PM

Read Original